A phase III randomized of Cloretazine (VNP40101M) [laromustine] and cytosine arabinoside (AraC) [cytarabine] in patients with acute myeloid leukemia in first relapse.

Trial Profile

A phase III randomized of Cloretazine (VNP40101M) [laromustine] and cytosine arabinoside (AraC) [cytarabine] in patients with acute myeloid leukemia in first relapse.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2013

At a glance

  • Drugs Laromustine (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 29 Aug 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12606000514505).
    • 29 Dec 2009 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 05 Nov 2009 Results reported in Blood.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top